Roots Analysis has done a detailed study on “AI-based Digital Pathology Market, 2022-2035”, covering key aspects of the market’s evolution and identifying potential future growth opportunities.
Key Market Insights
Presently, close to 80 players offering AI-based digital pathology services are available in the healthcare market which are located across the globe
In order to tap into the lucrative opportunity associated with AI-based digital pathology, various investment firms have invested over USD 1.7 billion in AI-based digital pathology market space, during the period 2016-2022
The estimated global demand for AI-based digital pathology is expected to grow at a CAGR of 9,4%, during 2022-2035
The projected future opportunity for companies engaged in this field is expected to be well distributed across different types of neural networks, types of assay, end-users, areas of applications, target disease indications, and key geographical regions
Table of Contents
1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Artificial Intelligence in Digital Pathology
3.3. Workflow of AI-based Digital Pathology
3.4. Applications of AI-based Digital Pathology Solutions
3.5. Regulatory Requirements Focused on AI-based Digital Pathology:
3.6. Challenges Associated with the Use of AI in Digital Pathology
3.7. Future Perspectives
4. AI-BASED DIGITAL PATHOLOGY: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. AI-based Digital Pathology Providers: Developers Landscape
4.3. AI-based Digital Pathology Providers: Market Landscape
5. AI-BASED DIGITAL PATHOLOGY MARKET: KEY INSIGHTS
5.1. Chapter Overview
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. PathAI
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook
6.3. Paige
6.4. Akoya Biosciences
6.5. PROSCIA
6.6. Visiopharm
6.7. Roche Tissue Diagnostics
6.8. Aiforia Technologies
6.9. Indica Labs
6.10. Ibex Medical Analytics
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Benchmarking of Portfolio Strength
7.5. Benchmarking of Funding Strength
7.6. Company Competitiveness Analysis: Small Players
7.7. Company Competitiveness Analysis: Mid-sized Players
7.8. Company Competitiveness Analysis: Large Players
8. FUNDING AND INVESTMENTS
8.1. Chapter Overview
8.2. Types of Funding
8.3. AI-based Digital Pathology: List of Funding and Investments
8.4. Concluding Remarks
9. DEMAND ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Global Demand for AI-based Digital Pathology, 2022-2035
9.4. Demand for AI-based Digital Pathology: Analysis by Geography
9.5. Demand for AI-based Digital Pathology: Analysis by Type of End-user
9.6. Concluding Remarks
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global AI-based Digital Pathology Market, 2022-2035
10.4. AI-based Digital Pathology Market: Analysis by Type of Neural Network, 2022 and 2035
10.5. AI-based Digital Pathology Market: Analysis by Type of Assay, 2022 and 2035
10.6. AI-based Digital Pathology Market: Analysis by Type of End-user, 2022 and 2035
10.7. AI-based Digital Pathology Market: Analysis by Area of Application, 2022 and 2035
10.8. AI-based Digital Pathology Market: Analysis by Target Disease Indication, 2022 and 2035
10.9. AI-based Digital Pathology Market: Analysis by Key Geographies, 2022 and 2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. aetherAI
12.3. CTL Clinitech Lab
12.4. Huron Digital Pathology
12.5. Mindpeak
12.6. Pramana
13. APPENDIX 1: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/ai-based-digital-pathology-market.html
Learn from experts: do you know about these emerging industry trends?
TIL Therapies: A New Paradigm in Cancer Treatment
Viral Clearance and Viral Testing Services
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Posts
The “Global Bioreactors and Fermenters Market, 2023-2035” report features an extensive study of the current market landscape and the likely future potential of the global bioreactors and fermenters market, over the next 12 years.
Key Inclusions
An executive summary of the insights captured during our research, offering a high-level view on the current state of the global bioreactors and fermenters market and its likely evolution in the mid-long term.
A general introduction to bioreactors and fermenters, along with details related to the components of a bioreactor. Additionally, the chapter presents information on different types of bioreactors based on type of bioprocess and mode of action. Further, it concludes with a discussion on applications of bioreactors and future perspectives in this domain.
A detailed assessment of the overall market landscape of companies manufacturing bioreactors and fermenters, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, geographical reach (North America, Europe, Asia-Pacific and Rest of the World), type of product (bioreactors and fermenters), bioreactor and fermenter capacity (micro-mini, small-scale, bench-scale, lab-scale, pilot-scale and large-scale), scale of operation of bioreactors and fermenters (preclinical, clinical and commercial), scalability of bioreactors and fermenters, type of bioprocess (batch, fed-batch and continuous), type of cell culture (2D cell culture, 3D cell culture and 4D cell culture), mode of operation of bioreactors and fermenters (manual, semi-automatic and automatic) and end users (academic institutes and research laboratories, biopharmaceutical and pharmaceutical industries, contract manufacturing organizations, and contract research organizations).
A detailed competitiveness analysis of bioreactor manufacturers and fermenter manufacturers based on manufacturer strength (in terms of number of years since the company was established and company size) and product portfolio strength (geographical reach, type of bioreactor or fermenter, bioreactor and fermenter capacity, type of bioprocess, scale of operation of bioreactors and fermenters, scalability of bioreactors and fermenters, mode of operation of bioreactors and fermenters, type of product, end user, and type of cell culture).
Elaborate profiles of key players manufacturing bioreactors and fermenters (shortlisted based on their bioreactor and fermenter manufacturing capabilities); each profile includes a brief overview of the company, along with information on its financial information (if available), product portfolio, recent developments and an informed future outlook.
An estimate of the global installed capacity of bioreactors and fermenters for biologics manufacturing, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of fabrication material (glass, stainless steel and single-use), source of cell culture (mammalian, microbial and others), reactor volume (less than 2,000 L, 2,000 to 5,000 L, 5,001 to 10,000 L and more than 10,000 L), type of manufacturer (in-house, hybrid and CMOs) and key geographical regions (North America, Europe, and Asia-Pacific and Rest of the World).
A case study on the market landscape of bioprocess controllers and automation systems, providing information on scale of operation (laboratory, clinical, and commercial), key features (scalability / ease to use, visual data display, remote accessibility, built-in system control sensors, expansive I/O compatibility and provisions for alarms / alerts), compatibility with bioreactor system (stirred tank (glass), single-use bioreactor, stirred tank (steel), fermenter, rocking motion), type of bioprocess (batch, fed-batch and perfusion), and type of process controlled (cell cultivation and microbial fermentation). In addition, the chapter presents details of companies involved in the development of bioprocess control software, upstream and downstream controllers, including information on their respective year of establishment, company size, and location of headquarters.
Stainless steel bioreactors hold a prominent share (~90%) of the current installed biomanufacturing capacity; majority of this is dedicated to the manufacturing of mammalian and microbial based therapeutics
The financial opportunity within the global bioreactors and fermenters market has been analyzed across the following segments:
Type of Product
Bioreactors
Fermenters
Fabrication Material
Glass
Stainless Steel
Single-use
Type of Bioprocess
Batch and Fed-batch
Continuous
Type of Biologic
Antibodies
Vaccines
Cell Therapies
Other Biologics
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
Key Questions Answered
Which are the top players in the global bioreactors and fermenters market?
What is the global market size of bioreactors and fermenters?
What are the factors driving the global bioreactors and fermenters market?
Which region has the highest market share in global bioreactors and fermenters market?
What are the leading market segments in global bioreactors and fermenters market?
Which segment, in terms of bioreactor / fermenter capacity, accounts for the largest share in the global bioreactors and fermenters market?
What is the growth rate (CAGR) in the global bioreactors and fermenters market?
What are the upcoming trends in the global bioreactors and fermenters market?
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/bioreactors-and-fermenters-market.html
Learn from experts: do you know about these emerging industry trends?
At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has done a detailed study on Gene Switch Market, 2023-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
Presently, close to 50 gene switch platforms are being developed for various applications in adoptive cell therapies (ACT), including CAR-Ts, TCRs and gene therapies; majority of them are protein-based gene switches
Various small molecules, including rimiducid, rapamycin and dasatinib, are being investigated to design safety switch for ACTs; management of treatment related toxicity has emerged as the key application of such platforms
The current market landscape is fragmented, featuring the presence of both new entrants and established players; presently, majority of the gene switch platform developers are based in North America
In pursuit of gaining a competitive edge, gene switch developers are presently undertaking several initiatives to expand their existing capabilities and augment respective product portfolios
The growing interest in this domain is evident from the rise in licensing agreements over the last few years; majority of such deals were signed between players based in North America
Several investors, having realized the opportunity within this domain, have invested over USD 3.5 billion across various funding rounds in the past five years
Scientific articles being published for gene switch, reflect the growing research efforts of various industry and academic stakeholders; majority of the authors are affiliated to organizations based in North America
More than 360 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field since 2014
Based on historical trends, we expect a steady growth in the licensing of gene switch platforms, in order to meet the growing demand for safe and effective gene therapies
The gene switch market is expected to grow at a CAGR of 11.5% till 2035; the overall opportunity is anticipated to be well distributed across various segments, such as types of target therapies, application areas and key regions
Table of Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Emergence of Gene Switch
3.3. Applications of Gene Switch
3.4. Challenges Associated with Gene Switch
3.5. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Gene Switch Platforms: Overall Market Landscape
4.3. Gene Switch Platform Developers: Developer Landscape
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis: Gene Switch Platforms
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. aceRNA Technologies
6.2.1. Company Overview
6.2.2. Gene Switch Platform Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Autolus Therapeutics
6.4. Bellicum Pharmaceuticals
6.5. Cellectis
6.6. Kiromic BioPharma
6.7. panCELLa
6.8. Precigen
6.9. Sana Biotechnology
6.10. Sangamo Therapeutics
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Gene Switch Platforms: Partnerships and Collaborations
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding
8.3. Gene Switch Platforms: Funding and Investments Analysis
9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Gene Switch Platforms: Recent Publications
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Gene Switch Platforms: Patent Analysis
10.4. Gene Switch Platforms: Patent Benchmarking Analysis
10.5. Gene Switch Platforms: Patent Valuation
10.6. Leading Patents: Analysis by Number of Citations
11. BUSINESS MODEL ANALYSIS
11.1. Chapter Overview
11.2. Gene Switch Platform Developers: Business Model Analysis
11.3. Concluding Remarks
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Gene Switch Platform Market, 2023-2035
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/gene-switch-market.html
Learn from experts: do you know about these emerging industry trends?
Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities
Medical Device Coatings and Modification Technologies
Learn from our recently published whitepaper:-
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has done a detailed study on “Cell and Gene Therapy CROs Market, 2022-2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
More than 105 CROs claim to provide a wide range of preclinical and clinical services for the development of advanced therapy medicinal products.
The current market landscape features the presence of established and emerging players, majority of the service providers offer research and analytical services for both cell and gene therapies at different scales of operation.
Around 1,330 cell and gene therapy focused clinical trials have been registered across the globe; most of the trials are focused on evaluating therapy candidates for the treatment of various oncological indications
In pursuit of a competitive edge and to eventually establish themselves as one-stop shops, stakeholders have actively entered into mutually beneficial partnerships
We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings
Our proprietary analysis highlights several potential acquisition partners for cell and gene therapy service providers across different geographies
Our proprietary total cost of ownership model provides an informed estimate of direct and indirect expenses for setting up a contract research facility in different regions, over a span of 20 years
The market is expected to grow at a CAGR of over 21% in the coming decade; the opportunity is likely to be well distributed across areas of expertise, therapeutic areas, scales of operation and key geographical regions
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Contract Research Organizations (CROs)
3.3. Type of Services Offered by CROs
3.4. Classification of CROs
3.5. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
3.6. Advantages of Outsourcing Operations to CROs
3.7. Risks Associated with Outsourcing to CROs
3.8. Future Perspectives
4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Cell and Gene Therapy Research
4.3. Guiding Models of Outsourcing
4.4. Selecting an Appropriate Outsourcing Model
4.5. Selecting a CRO Partner
4.6. Role of CROs in Drug Development
4.7. Concluding Remarks
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Allucent (Formerly Known as CATO SMS)
6.2.3. Charles River Laboratories
6.2.4. Creative Biolabs
6.2.5. IQVIA
6.2.6. Medpace
6.2.7. PPD
6.2.8. Precision for Medicine
6.2.9. QPS
6.3. Players based in Europe
6.3.2. Evotec
6.3.3. ICON
6.3.4. Syneos Health
6.4. Players based in Asia-Pacific
6.4.1. CMIC Group
6.4.2. Labcorp
7. COMPETITIVE BENCHMARKING
7.1. Chapter Overview
7.2. Assumptions and Key Methodology
7.3. Competitive Benchmarking by Region
7.4. Concluding Remarks
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell and Gene Therapy CROs: Partnerships and Collaborations
9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scoring Criteria and Key Assumptions
10.3. Scope and Methodology
10.4. Potential Strategic Acquisition Targets Amongst Small Players
10.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players
11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scoring Criteria and Key Assumptions
11.3. Scope and Methodology
11.4. Key Potential Strategic Partners for Cell Therapy CROs
12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scoring Criteria and Key Assumptions
12.3. Scope and Methodology
12.4. Key Potential Strategic Partners for Gene Therapy CROs
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.5. Gene Therapies: Analysis by Number of Clinical Trials
13.6. Gene Therapies: Analysis by Enrolled Patient Population
14. TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT RESEARCH ORGANIZATIONS
14.1 Chapter Overview
14.2. Key Parameters
14.3. Assumptions and Methodology
14.4 Sample dataset for the estimation of total cost of ownership
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Global Cell and Gene Therapy CROs Market, 2022-2035
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
17. CONCLUSION
17.1. Chapter Overview
18. INTERVIEW AND SURVEY TRANSCRIPTS
18.1. Chapter Overview
18.2. CATO SMS
18.3. Changhai Hospital, Second Military Medical University
18.4. University of Colorado
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html
Learn from experts: do you know about these emerging industry trends?
Key Trends in Non-Viral Transfection Market
Deep Learning-based Interoperability: Advanced Neural Networks Mimicking the Human Brain
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has done a detailed study on Cell Therapy Media, Kits, Reagents and Surfaces Market, 2023-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
Leveraging their expertise, over 450 types of kits, media, reagents and extracellular matrices have been manufactured by consumable providers for research and therapeutic purposes
The market features the presence of more than 80 firms across the globe; majority of these stakeholders are emerging players based in North America
A larger proportion of the kits available in the cell therapy domain comprise of different types of reagents; of these, 60% are intended for use with stem cell therapies and nearly 80% are stored in refrigerated conditions
Media developers are offering products for a broad range of cell therapies; nearly 90% of such players are providing media in the volume range of 100 to 500 ml
Predominantly, the cell therapy reagents are intended to be used at discovery scale of operation for a wide spectrum of functions, including cell expansion and proliferation
The market landscape of matrices, which typically have a shelf life of 1 to 1.5 years, is well distributed in terms of type of ECM coating and type of formulation
In pursuit of gaining a competitive edge, cell therapy consumable providers are upgrading their existing technologies and expanding their product portfolios
Many companies have undertaken strategic initiatives, including partnerships, acquisitions and expansions, to augment their existing capabilities
We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings
Over the years, stakeholders within this industry have established strong brand positions by undertaking a range of initiatives to further advance the development of raw materials for cell therapies
Cost is a key determinant for the adoption of consumables in a cell therapy manufacturing process; the pricing strategy matrix is likely to assist players in evaluating the competitive market prices for their products
In 2035, the commercial scale of operation is likely to account for 75% of the total demand for cell therapy surface; this is attributed to the expected surge in the anticipated approvals of multiple cell therapies
A paradigm shift from animal-based to animal component free formulations, combined with stringent regulatory guidelines, is likely to drive the growth of the cell therapy media market at an annualized rate of 12%
The projected future opportunity for cell therapy consumable providers is expected to be well distributed across different types of end-users and key geographical regions
Table of Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Cell Therapies
3.3. Comparison of Cell Therapies with Other Biopharmaceuticals
3.4. Classification of Cell Therapy Products
3.5. Overview of Cell Therapy Development and Manufacturing
3.6. Role of Raw Materials in Cell Therapy Development and Manufacturing
3.7. Types of Cell Therapy Consumables
3.8. Key Challenges Associated with Manufacturing of Cell Therapy Consumables
3.9. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Cell Therapy Kit Providers
4.3. List of Cell Therapy Media Providers
4.4. List of Cell Therapy Reagent Providers
4.5. List of Cell Therapy Extracellular Matrix Providers
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Methodology
5.4. Cell Therapy Consumables Providers: Company Competitiveness Analysis
5.5. Cell Therapy Kits Providers
5.6. Cell Therapy Media Providers
5.7. Cell Therapy Reagent Providers
5.8. Cell Therapy Extracellular Matrix Providers
6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Brand Positioning: STEMCELL Technologies
6.4. Brand Positioning: Miltenyi Biotec
6.5. Brand Positioning: Thermo Fisher Scientific
6.6. Brand Positioning: Takara Bio
6.7. Brand Positioning: GeminiBio
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. STEMCELL Technologies
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Miltenyi Biotec
7.4. Thermo Fisher Scientific
7.5. Bio-Techne
7.6. Irvine Scientific
7.7. Lonza
7.8. Sartorius
7.9. BD Biosciences
7.10. Corning
7.11. CellGenix
8. RECENT DEVELOPMENTS AND INITIATIVES
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell Therapy Consumables: Partnerships and Collaborations
8.4. Cell Therapy Consumables: Mergers and Acquisitions
8.5. Cell Therapy Consumables: Recent Expansions
9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS
9.1. Chapter Overview
9.2. Scoring Criteria and Key Assumptions
9.3. Scope and Methodology
9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
10. ROOTS ANALYSIS PRICING STRATEGY
10.1. Chapter Overview
10.2. Roots Analysis Framework
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Demand for Cell Therapy Consumables
11.4. Analysis by Scale of Operation
11.5. Analysis by Geography
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Cell Therapy Consumables Market, 2023-2035
12.4. Cell Therapy Consumables Market: Analysis by Type of Product
12.5. Cell Therapy Consumables Market: Analysis by Type of Cell Therapy
12.6. Cell Therapy Consumables Market: Analysis by Scale of Operation
12.7. Cell Therapy Consumables Market: Analysis by Type of End-User
12.8. Cell Therapy Consumables Market: Analysis by Geography
13. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
13.1. Chapter Overview
13.2. Emerging Trends Related to Cell Culture Media
13.3. Automation of Cell Therapy Manufacturing Processes
13.4. Single Use Systems and Technologies in Cell Therapy Manufacturing
14. CONCLUDING REMARKS
15. INTERVIEW TRANSCRIPTS
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.html
Learn from experts: do you know about these emerging industry trends?
Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has done a detailed study on Cell Therapy Media, Kits, Reagents and Surfaces Market, 2023-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
Leveraging their expertise, over 450 types of kits, media, reagents and extracellular matrices have been manufactured by consumable providers for research and therapeutic purposes
The market features the presence of more than 80 firms across the globe; majority of these stakeholders are emerging players based in North America
A larger proportion of the kits available in the cell therapy domain comprise of different types of reagents; of these, 60% are intended for use with stem cell therapies and nearly 80% are stored in refrigerated conditions
Media developers are offering products for a broad range of cell therapies; nearly 90% of such players are providing media in the volume range of 100 to 500 ml
Predominantly, the cell therapy reagents are intended to be used at discovery scale of operation for a wide spectrum of functions, including cell expansion and proliferation
The market landscape of matrices, which typically have a shelf life of 1 to 1.5 years, is well distributed in terms of type of ECM coating and type of formulation
In pursuit of gaining a competitive edge, cell therapy consumable providers are upgrading their existing technologies and expanding their product portfolios
Many companies have undertaken strategic initiatives, including partnerships, acquisitions and expansions, to augment their existing capabilities
We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings
Over the years, stakeholders within this industry have established strong brand positions by undertaking a range of initiatives to further advance the development of raw materials for cell therapies
Cost is a key determinant for the adoption of consumables in a cell therapy manufacturing process; the pricing strategy matrix is likely to assist players in evaluating the competitive market prices for their products
In 2035, the commercial scale of operation is likely to account for 75% of the total demand for cell therapy surface; this is attributed to the expected surge in the anticipated approvals of multiple cell therapies
A paradigm shift from animal-based to animal component free formulations, combined with stringent regulatory guidelines, is likely to drive the growth of the cell therapy media market at an annualized rate of 12%
The projected future opportunity for cell therapy consumable providers is expected to be well distributed across different types of end-users and key geographical regions
Table of Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Cell Therapies
3.3. Comparison of Cell Therapies with Other Biopharmaceuticals
3.4. Classification of Cell Therapy Products
3.5. Overview of Cell Therapy Development and Manufacturing
3.6. Role of Raw Materials in Cell Therapy Development and Manufacturing
3.7. Types of Cell Therapy Consumables
3.8. Key Challenges Associated with Manufacturing of Cell Therapy Consumables
3.9. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Cell Therapy Kit Providers
4.3. List of Cell Therapy Media Providers
4.4. List of Cell Therapy Reagent Providers
4.5. List of Cell Therapy Extracellular Matrix Providers
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Methodology
5.4. Cell Therapy Consumables Providers: Company Competitiveness Analysis
5.5. Cell Therapy Kits Providers
5.6. Cell Therapy Media Providers
5.7. Cell Therapy Reagent Providers
5.8. Cell Therapy Extracellular Matrix Providers
6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Brand Positioning: STEMCELL Technologies
6.4. Brand Positioning: Miltenyi Biotec
6.5. Brand Positioning: Thermo Fisher Scientific
6.6. Brand Positioning: Takara Bio
6.7. Brand Positioning: GeminiBio
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. STEMCELL Technologies
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Miltenyi Biotec
7.4. Thermo Fisher Scientific
7.5. Bio-Techne
7.6. Irvine Scientific
7.7. Lonza
7.8. Sartorius
7.9. BD Biosciences
7.10. Corning
7.11. CellGenix
8. RECENT DEVELOPMENTS AND INITIATIVES
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell Therapy Consumables: Partnerships and Collaborations
8.4. Cell Therapy Consumables: Mergers and Acquisitions
8.5. Cell Therapy Consumables: Recent Expansions
9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS
9.1. Chapter Overview
9.2. Scoring Criteria and Key Assumptions
9.3. Scope and Methodology
9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
10. ROOTS ANALYSIS PRICING STRATEGY
10.1. Chapter Overview
10.2. Roots Analysis Framework
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Demand for Cell Therapy Consumables
11.4. Analysis by Scale of Operation
11.5. Analysis by Geography
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Cell Therapy Consumables Market, 2023-2035
12.4. Cell Therapy Consumables Market: Analysis by Type of Product
12.5. Cell Therapy Consumables Market: Analysis by Type of Cell Therapy
12.6. Cell Therapy Consumables Market: Analysis by Scale of Operation
12.7. Cell Therapy Consumables Market: Analysis by Type of End-User
12.8. Cell Therapy Consumables Market: Analysis by Geography
13. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
13.1. Chapter Overview
13.2. Emerging Trends Related to Cell Culture Media
13.3. Automation of Cell Therapy Manufacturing Processes
13.4. Single Use Systems and Technologies in Cell Therapy Manufacturing
14. CONCLUDING REMARKS
15. INTERVIEW TRANSCRIPTS
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.html
Learn from experts: do you know about these emerging industry trends?
Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The rising demand for greater data reproducibility, accuracy and increased efficiency have prompted the healthcare laboratories to consider shifting from manually-handled processes to using lab automation systems.
Roots Analysis is pleased to announce the publication of its recent study, titled, “Lab Automation Market, 2023-2035”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these lab automation systems over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of lab automation system manufacturers engaged in the manufacturing of various lab automation systems.
A detailed competitiveness analysis of lab automation system manufacturers based on several relevant parameters, such as company strength, product diversity and product strength.
Elaborate profiles of key players (shortlisted based on a proprietary criterion) engaged in the development of lab automation system across North America, Europe and Asia-Pacific and Rest of the World. Each profile features a brief overview of the company, details related to its financial information (if available), product portfolio, recent developments and an informed future outlook.
A detailed analysis of partnerships inked between stakeholders engaged in this domain since 2018, based on several relevant parameters, such as year of partnership, type of partnership, type of partner, type of automation instrument(s), most active players (in terms of number of partnerships) and regional distribution of partnership activity in this domain.
An in-depth analysis of various patents that have been filed / granted related to lab automation since 2018, taking into consideration several relevant parameters, such as patent publication year, type of patent, patent jurisdiction, CPC symbols, type of applicant, emerging focus areas and leading players (in terms of number of patents filled / granted) and leading individual assignees. It also features a detailed patent benchmarking analysis and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
A case study on the lab automation software providers, providing detailed analysis on various parameters such as year of establishment, company size (in terms of number of employees), location of headquarters, type of software, mode(s) of deployment, end-user(s).
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Stage of Automation
Pre-Analytical Stage
Analytical Stage
Post-Analytical Stage
Total Lab Automation
Type of Instrument
Automated Liquid Handling Systems
Automated Microplate Readers
Automated Sampling Systems
Analyzers
Automated Storage and Retrieval Systems (ASRS)
Other Instruments
End-User
Pharmaceutical and Biotechnology Companies
Research and Diagnostic Laboratories
Other End-Users
Key Geographical Region
North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America
Key companies covered in the report
Abbott
Anton Paar
BD
Beckman Coulter
ERWEKA
Leuze
Ortho Clinical Diagnostics
Pall Corporation
PerkinElmer
Roche Diagnostics
Siemens Healthineers
SYSTAG
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/lab-automation-market.html
News article
Digital Biomanufacturing Market
Learn from experts: do you know about these emerging industry trends?
SARM1: A Potential Therapeutic Target For Neurodegenerative Diseases
Novel Cell Cytometers: Need of the Hour
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The “Conjugation and Labeling Services Market: Focus on Protein Labeling, Peptide Labeling, Small Molecule Conjugation and Antibody Conjugation, 2023-2035” report features an extensive study of the current market landscape, market size and the likely future potential of the conjugation and labeling services market, during the forecast period.
Key Inclusions
An executive summary of the insights captured during our research. It offers a high-level view on the current state of conjugation and labeling services market and its likely evolution in the mid-long term.
A general overview of conjugation and labeling of biomolecules, highlighting the various advantages of biomolecule conjugation and labeling. It also provides details on the different types of biomolecular conjugates and labels. Further, the chapter concludes with a discussion on various applications of the conjugated and labeled biomolecules in the biotechnology and pharmaceutical industry.
A detailed assessment of the overall market landscape of the companies offering conjugation and labeling services, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of molecule(s) supported (proteins, peptides, small molecules, antibodies and other molecules), type of molecular conjugate(s) / label(s) (polymers, haptens, enzymes, fluorescent tags, FRET pairs, quantum dots, carrier proteins, streptavidin, chelators, bead coupling / particle conjugates, isotopes, photoreactives and other molecular conjugates / labels) and conjugation service(s) offered.
A company competitiveness analysis of conjugation and labeling service providers based on company strength (in terms of years of experience and company size) and service strength (in terms of type of molecule(s) supported, type of molecular conjugate(s) / label(s) and conjugation service(s) offered).
Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) offering conjugation and labeling services, located across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, recent developments and an informed future outlook.
A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018, covering acquisitions, service agreements, product development agreements, technology licensing agreements, and other relevant agreements.
An in-depth analysis of recent events (webinars / conferences / seminars / meetings / symposiums / summits) that were organized for stakeholders in the bioconjugation domain, based on several relevant parameters, such as year of event, event platform, type of event, geography, key focus areas, most active event organizers, active industry and non-industry players (in terms of number of speakers), seniority level of event speakers and geographical mapping of upcoming events.
A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall conjugation and labeling services market.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of Molecule
Proteins
Peptides
Small Molecules
Antibodies
Other Molecules
Type of Molecular Conjugate / Label
Polymers
Haptens
Enzymes
Fluorescent Tags
Bead Coupling / Particle Conjugates
Quantum Dots
Isotopes
Other Molecular Conjugates / Labels
Key Geographical Regions
North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America
Frequently Asked Questions
What is the global market size of antibody conjugation services market?
Which are the leading companies in the antibody conjugation services market?
How many companies offer peptide conjugation services?
What percentage of service providers are engaged in offering conjugation and labeling services with both fluorescent tags and enzymes?
How many service providers offer services related to antibody-enzyme bioconjugation?
What are the major factors driving the conjugation and labeling services market?
What are the leading market segments in the conjugation and labeling services market?
Which region captures the highest share in the conjugation and labeling services market?
What is the likely growth rate (CAGR) for conjugation and labeling services market?
For additional details, please visit https://www.rootsanalysis.com/reports/conjugation-and-labeling-services-market.html
News article
Bioavailability Enhancement Services Market
Learn from experts: do you know about these emerging industry trends?
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends
Novel Cell Cytometers: Need of the Hour
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Owing to the growing number of clinical trials and complexities associated with patient enrollment, drug developers are increasingly relying on patient recruitment service providers to expediate the drug development timelines
Roots Analysis is pleased to announce the publication of its recent study, titled, “Patient Recruitment and Retention Services Market (3rd Edition), 2022 – 2035.”
The report features an extensive study of companies engaged in offering patient recruitment services and patient retention services. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:
A general overview of the clinical trials, patient recruitment process, patient recruitment associated services as well as the patient retention strategies employed to prevent drop-out of enrolled individuals from clinical trials.
A brief information on the various types of patient outreach methods used by contract service providers in this domain, to identify and enroll patients in clinical trials.
A detailed assessment of the overall landscape of patient recruitment companies and patient retention companies offering these services.
A detailed competitiveness analysis of patient recruitment and retention service providers, segregated into three peer groups based on company size (small, mid-sized, and large and very large).
Elaborate profiles of prominent players offering patient recruitment and retention service, based in North America, Europe and Asia Pacific.
An analysis of the partnerships that have been inked by stakeholders engaged in this domain, from 2013-2022.
A review of the emerging trends in the patient recruitment industry, including the use of social media, mobile technologies, electronic health records (EHR), real-world evidence (RWE) and artificial intelligence.
A detailed discussion on the key growth opportunities in the field of patient recruitment and retention that are likely to impact the evolution of the market over the coming years.
A case study on regulatory landscape of patient recruitment, highlighting the regulatory process, guidelines and framework.
A brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases.
A detailed analysis of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
A detailed assessment on the impact of the COVID-19 pandemic on the patient recruitment and retention services market.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Patient Recruitment Step
Pre-screening
Screening
Trial Phase
Phase I
Phase II
Phase III
Phase IV
Therapeutic Area
Cardiovascular Disorders
Oncological Disorders
Infectious Diseases
CNS Disorders
Respiratory Disorders
Hematological Disorders
Dermatological Disorders
Ophthalmic Disorders
Others
Key Geographical Regions
North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Susan Fitzpatrick-Napier (Founder and Director, TrialWire)
Kate Shaw (Chief Executive Officer and Founder) and Marco Lassandro (Marketing and Communications Manager, Innovative Trials)
Simon Klaasen (Co-founder and Managing Director, Link2Trials)
Stefan Mayer-Eggersmann (Chief Commercial Officer, Clariness)
Ken Shore (Chief Commercial Officer, Continuum Clinical)
Hagit Nof (Chief Operation Officer and Business Development Officer, nRollmed)
Paul Ivsin (Ex-Managing Director, Seeker Health)
Kasturi Lakhe (Inside Sales Specialist, EVERSANA)
Key companies covered in the report
BBK Worldwide
Continuum Clinical
IQVIA
United BioSource (UBC)
WCG ThreeWire
Clariness
Fidelis Research
Ignite Data
Innovative Trials
Orphan Reach
3H Medi Solution
Buzzreach
Current Medical Information Center (CMIC)
nRollmed
Trialfacts
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market/245.html
News article
Global Cell Free Expression Market
Learn from experts: do you know about these emerging industry trends?
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
Given the potential of digital twins to replicate the physical world in a digital layout, as well as their ability to provide real-time outputs, while gathering constant inputs from the real-world, such products have generated significant interest within the healthcare domain
The USD 29.8 billion (by 2035) financial opportunity within digital twin market has been analyzed across the following segments:
Therapeutic Area
Cardiovascular Disorders
Metabolic Disorders
Orthopedic Disorders
Other Disorders
Type of Digital Twin
Process Twins
System Twins
Whole Body Twins
Body Part Twins
Area of Application
Asset / Process Management
Personalized Treatment
Surgical Planning
Diagnosis
Other Applications
End Users
Pharmaceutical Companies
Medical Device Manufacturers
Healthcare Providers
Patients
Other End Users
Key Geographical Regions
North America
Europe
Asia
Latin America
Middle East and North Africa
Rest of the World
The Digital Twins Market, 2022-2035, report features the following companies, which we identified to be key players in this domain:
Babylon
ExactCure
ImmersiveTouch
Navv Systems
ThoughtWire
Unlearn.AI
The latest report also provides key insights for Digital Twin Technology and Digital Twins Providers
Table of Contents
Preface
Executive Summary
Introduction
Market Landscape
Key Insights
Company Competitiveness Analysis
Company Profiles
Partnerships and Collaborations
Funding and Investments Analysis
Berkus Start-up Valuation Analysis
Market Forecast
Conclusion
Executive insights
Appendix I: Tabulated data
Appendix II: List of Companies and Organizations
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/digital-twins-market.html
You may also be interested in the following titles:
Buffer Preparation Market
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends
Quantum Computing in Drug Discovery Services Market
Roots Analysis Consulting - the preferred research partner for global firms
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.
Key Market Insights
Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases
Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration
Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide
Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players
A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain
Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics
Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017
The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions
Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics
The bacteriophage market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions
Table of Content
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bacteriophages
3.3. Biology of Bacteriophages
3.4. Introduction to Bacteriophage Therapy
3.5. Applications of Bacteriophage Therapy
3.6. Advantages of Bacteriophage Therapy
3.7. Limitations of Bacteriophage Therapy
3.8. Conclusion
4. BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Bacteriophage Therapeutics: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Phase of Development and Therapeutic Area
4.2.4. Analysis by Targeted Bacterial Strain
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Route of Administration
4.3. Information on Bacteriophage Related Technologies
5. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE
5.1. Chapter Overview
5.2. Bacteriophage Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics
6. COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. Eliava BioPreparations
6.3. Micreos
6.4. NPO Microgen
6.5. ContraFect
6.6. Adaptive Phage Therapeutics
6.7. Phagelux
6.8. Pherecydes Pharma
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Bacteriophage Therapeutics Market: Clinical Trial Analysis
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Bacteriophage Therapeutics: Patent Analysis
8.4. Bacteriophage Therapeutics: Patent Benchmarking
8.5. Bacteriophage Therapeutics: Patent Valuation
8.6. List of Leading Patents
9. PUBLICATION BENCHMARKING ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Publication Benchmarking
10. ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bacteriophage Therapeutics: Academic Grant Analysis
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Bacteriophage Therapeutics Market: List of Funding and Investments
11.4. Concluding Remarks
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
13. START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Bacteriophage Therapeutics Developers: Start-ups
13.3. Benchmarking of Start-ups
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Assumptions
14.3. Forecast Methodology
14.4. Global Bacteriophage Therapeutics Market, 2022-2035
15. CONCLUSION
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Rime Bioinformatics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Antoine Culot, Chief Executive Officer
16.3. BiomX
16.4. Hospices Civils De Lyon
16.5. Independent Consultant
17. APPENDIX I: TABULATED DATA
18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html
You may also be interested in the following titles:
Nanoparticle Formulation Market
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends
Cell Therapy Manufacturing Market
Roots Analysis Consulting - the preferred research partner for global firms
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has done a detailed study on Deep Learning in Drug Discovery and Deep Learning in Diagnostics Market, covering important aspects of the industry and identifying key future growth opportunities.
Key Market Insights
Presently, more than 70 players across the globe claim to offer deep learning technologies for potential applications across various steps of drug discovery and development process
Majority (70%) of the stakeholders employ proprietary deep learning-based technologies in drug discovery to offer big data analysis
Nearly 50% of the deep learning-based diagnostic providers are based in North America; most such players offer technologies for use across medical imaging and medical diagnosis related applications
Around 70% of the players engaged in offering deep learning solutions for diagnostics have been established post-2011; majority of the players offer solutions focused on oncological disorders
Foreseeing the lucrative potential, a large number of players have made investments worth over USD 15 billion, across 210 funding instances, to advance the initiatives undertaken by industry stakeholders
Over the past few years, more than 704,000 patients have been recruited / enrolled in clinical trials registered for deep learning-based solutions / diagnostics across different geographies
Our proprietary benchmarking analysis, based on a variety of parameters, indicates the leading start-ups / small firms that are spearheading innovation in this domain
Some players have managed to establish strong competitive positions; in the near future, we expect multiple acquisitions to take place wherein the relative valuation of a firm is likely to be a key determinant
Increasing adoption of deep learning technologies in the life sciences and healthcare industry is anticipated to create profitable business opportunities for the technology developers
The market opportunity associated with deep learning in drug discovery is expected to witness an annualized growth rate of 23% over the coming 12 years
In the long term, the opportunity for deep learning in diagnostics is projected to grow exponentially; the market is likely to be well distributed across various therapeutic areas and geographical regions
Table of Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Humans, Machines and Intelligence
3.2. The Science of Learning
3.3. The Big Data Revolution
3.4. Deep Learning in Healthcare
3.5. Concluding Remarks
4. MARKET OVERVIEW: DEEP LEARNING IN DRUG DISCOVERY
4.1. Chapter Overview
4.2. Deep Learning in Drug Discovery: Overall Market Landscape of Service / Technology Providers
5. MARKET OVERVIEW: DEEP LEARNING IN DIAGNOSTICS
5.1. Chapter Overview
5.2. Deep Learning in Diagnostics: Overall Market Landscape of Service / Technology Providers
6. COMPANY PROFILES
6.2. Aegicare
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Aiforia Technologies
6.4. Ardigen
6.5. Berg
6.6. Google
6.7. Huawei
6.8. Merative
6.9. Nference
6.10. Nvidia
6.11. Owkin
6.12. Phenomic AI
6.13. Pixel AI
7. PORTER’S FIVE FORCES ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Assumptions
7.3. Key Parameters
7.4. Concluding Remarks
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3 Deep Learning Market: Clinical Trial Analysis
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Deep Learning Market: Funding and Investment Analysis
10. START-UP HEALTH INDEXING
10.1. Chapter Overview
10.2. Start-ups Focused on Deep Learning in Drug Discovery
10.3. Benchmarking Analysis of Start-ups Focused on Deep Learning in Drug Discovery
10.4. Start-ups Focused on Deep Learning in Diagnostics
10.5. Benchmarking Analysis of Start-ups Focused on Deep Learning in Diagnostics
10.5.1. Analysis by Focus Area
11. COMPANY VALUATION ANALYSIS
11.1. Chapter Overview
11.2. Company Valuation Analysis: Key Parameters
11.3. Methodology
11.4. Company Valuation Analysis: Roots Analysis Proprietary Scores
12. MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DRUG DISCOVERY
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Deep Learning in Drug Discovery Market, 2023-2035
13. MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DIAGNOSTICS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Deep Learning in Diagnostics Market, 2023-2035
14. DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS
15. CONCLUDING REMARKS
16. INTERVIEW TRANSCRIPTS
16.1. Chapter Overview
16.2. Nucleai
16.3. Mediwhale
16.4. Arterys
16.5. AlgoSurg
16.6. ContextVision
16.7. Advenio Technosys
16.8. Arterys
16.9. Arya.ai
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html
You may also be interested in the following titles:
Decentralized Clinical Trials / Virtual Clinical Trials Market
Exploring AI-based Digital Pathology
Medical Device Coatings Market
Roots Analysis Consulting - the preferred research partner for global firms
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The growing concern of patient non-compliance and poor adherence to conventional medication regimen has prompted various biopharmaceutical companies to leverage the expertise of players offering long-acting drug delivery technologies and services
Roots Analysis is pleased to announce the publication of its recent study, titled, “Long-Acting Drug Delivery Market, 2023-2035”
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes
An executive summary of the insights captured during our research. It offers a high-level view on the current state of long acting drugs delivery technologies and services market and its likely evolution in the mid-long term.
A general overview of long-acting drug delivery and the different types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery.
A detailed assessment of the current technology landscape of long-acting drug delivery technologies.
A detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery.
A technology competitiveness analysis of long-acting drug delivery technologies.
A company competitiveness analysis of long-acting drug delivery service providers.
Elaborate profiles of prominent players developing technologies and offering services in the domain of long-acting drug delivery (shortlisted based on a proprietary criterion).
A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018.
A detailed analysis of over 570 peer-reviewed, scientific articles focused on research related to long-acting drug delivery.
An in-depth analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018.
A detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Principle
Manipulation of drug release from delivery systems
Manipulation of in vivo clearance
Strategy
Chemical Modification
Micro-encapsulation
Long-Acting Hydrogels
Long-Acting Implants
Long-Acting Microneedles
Multivesicular Liposomes
Nanocrystal Suspensions
Protein Fusion
Compatible Dosage Form
Injectables
Implantables
Oral Dosage Forms
Topical / Transdermal Dosage Forms
Vaginal Dosage Forms
Other Dosage Forms
Type of Molecules Delivered
Small Molecules
Biologics
Other Molecules
Type of Material Used
Polymer based
Non-polymer based
Key Geographical Regions
North America
Europe
Asia-Pacific
Middle East and North Africa
Key companies covered in the report
Adare Pharma Solutions
AMW
Bostal Drug Delivery
Creative Biolabs
ForDoz Pharma
Innocore Pharmaceuticals
Integral BioSystems
LATITUDE Pharmaceuticals
Navin Saxena Research and Technology Centre (NSRT)
Samyang Biopharm
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market.html
You may also be interested in the following titles:
Oral Solid Dosage Manufacturing Market
Lipid Nanoparticles in Drug Delivery
Bioavailability enhancement services market
Global Gene Switch Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The “Bispecific Antibodies Market report features an in-depth analysis, highlighting the pipeline of various players engaged in this domain.
Roots Analysis has announced the addition of “Bispecific Antibodies Market, 2023-2035” report to its list of offerings.
Key Inclusions
A detailed review of the market landscape of over 220 bispecific antibodies that are either approved or being evaluated in different stages of clinical development, based on several relevant parameters, such as developer company, phase of development, target antigen, type of therapy, route of administration, method of administration, target indication, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer.
An in-depth assessment of the market landscape of over 180 bispecific antibodies that are currently being evaluated in preclinical studies, based on several relevant parameters, such as developer company, stage of development, target antigen, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer.
A detailed assessment of over 80 technology platforms being developed / used by various drug developers for the production of bispecific antibody therapeutics, featuring a 3-D comparative bubble analyses of bispecific antibody technology platforms based on multiple relevant parameters, such as clinical / preclinical pipeline strength, developer’s years of experience, company size and location of headquarters of developers.
An in-depth analysis of big pharma players engaged in this domain, featuring insightful spider web analyses of such players, based on clinical stage competition, marketed drugs competition, clinical trial activity, partnership activity and technology portfolio strength. Additionally, it features heat map analyses, highlighting the comparison of big pharma players based on various relevant parameters, such as target antigen, antibody format, mechanism of action and target therapeutic area.
Elaborate profiles of prominent drug developers engaged in the development of bispecific antibodies, featuring a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key members of the executive team, financial details / information (if available), drug portfolio, recent developments and an informed future outlook.
An insightful analysis of various partnerships inked between stakeholders engaged within the bispecific antibody therapeutics domain, during the period 2016-2023, based on several relevant parameters, such as year of partnership, type of partnership, disease segment, type of payment model employed, deal amount, most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity.
An in-depth analysis of ongoing and planned studies related to bispecific antibody therapeutics, which were registered till April 2023, taking into consideration several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, type of study, study design, type of sponsor / collaborator, leading industry and non-industry players, key focus areas and geographical location of trials.
A review of different channels used for promoting marketed bispecific antibodies, along with examples of players that have undertaken such initiatives, elaborating on the various promotional strategies being adopted by developers of two approved bispecific antibodies (chosen based on their popularity in this domain), namely Blincyto™ and Hemlibra®, and comparison of both the drugs based on information available on their respective websites.
A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall market.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Therapeutic Area
Autoimmune Disorders
Genetic Disorders
Hematological Malignancies
Ophthalmic Disorders
Skin Cancers
Solid Tumors
Mechanism of Action
Cytokines Retargeting / Neutralization
Dual Ligands Blocking
Resistance Factors Co-targeting
Targeting Tumor Angiogenesis
T-Cell Retargeting / Activation
Others
Target Antigen
C5-Albumin
CD20 x CD3
CD3 x BCMA
CD3 x CD19
EGFR x cMET
EpCAM x CD3
Factor IXa x Factor X
gp100 x CD3
HER2 x HER2
PD-1 x CTLA-4
PD-L1 x TGFβ
TNF-α x HSA
VEGF x DLL4
VEGF-A x ANG2
Antibody Format
Asymmetric
Fragments
Key Players
Akeso Biopharma
Alexion
Amgen
Genmab
Immunocore
Janssen Research & Development
Linton Pharm
Merck
OncXerna Therapeutics
Pfizer
Roche
Taisho Pharmaceutical
Zymeworks
Key Geographical Regions
Asia
Europe
North America
Rest of the World
Key Questions Answered
What is the overall size of the global bispecific antibody therapies market?
What is the rate at which the bispecific antibodies market is likely to grow in the coming years?
Which region has the highest growth rate in the bispecific antibodies market?
Who are the leading players engaged in this market?
How many players are engaged in developing bispecific antibodies?
What are the most common antigens targeted by bispecific antibody therapeutics?
Which target indication covers the largest share in bispecific antibody therapies market?
What is the partnership and collaboration trend in the bispecific antibody therapeutics domain?
What are the upcoming trends in bispecific antibody therapies market?
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
You may also be interested in the following titles:
Medical Device Coatings and Surface Modification Technologies Market
mRNA Synthesis and Manufacturing Services Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The “Investor Series: Opportunities in Women’s Digital Health Market’’ report provides detailed information on the women’s digital health market, covering the core and peripheral women’s digital health solutions
Key Inclusions
An executive summary of the insights captured during our research. It offers a high-level view on the current state of women’s digital health market and its likely evolution in the mid-long term along with the financial activity in this domain.
An introduction to women’s digital health, highlighting some of the key application areas of the FemTech industry. It features various types of women’s digital health products / solutions that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of women’s digital health solutions, and the opinions of representatives from key stakeholder companies involved in this domain.
A detailed analysis of women’s digital health focused companies that were established post-2006, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size, and type of venture.
An assessment of the various products / solutions, offered by the innovator companies, featuring analysis based on number and types of products. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity, estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research.
An informed perspective on the value proposition of the companies captured in the report based on multiple relevant aspects, namely product-related value, value to patients, developer value and outreach-related value.
A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing women’s digital health solutions. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
A detailed analysis of the women's digital health funding women's digital health investment activity that has taken place, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies mentioned in the report. Further, it features a list of the leading investors in women’s digital health, based on their participation in financing activity in this industry segment.
An elaborate review of the overall women’s digital health market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.
A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and others (social, economic, environmental and political risks).
A case study where investors have exited various women’s digital health-related ventures, offering insights on return on investments received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the women’s digital health market.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of Solution
Applications / Software
Devices
Services
Therapeutic Application Area
Fetal Health
General Wellness
Menstrual Cycle
Pelvic Care
Reproductive Health / Fertility
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa
Key Questions Answered
What are the key application areas of the FemTech industry?
Who are the innovators offering women’s digital health solutions?
What type of women’s digital health products / solutions are being offered by the innovator companies?
What are the key value propositions offered by players engaged in the women’s digital health domain?
What is the relative competitiveness of different players offering products / solutions focused on women’s health?
Who are the key investors that are actively supporting the development and commercialization of women’s digital health products / solutions?
What are the anticipated fundamental and technical trends of financial data of publicly listed companies within the innovator landscape?
Who are the potential acquisition targets for investors in the women’s digital health sector?
What are the major risks for investors seeking to tap into the women’s digital health domain?
What is the estimated return on investments received by the investors?
How is the current and future market opportunity related to women’s digital health likely to be distributed across key market segments?
Get more details on the report https://www.rootsanalysis.com/reports/opportunities-in-women-digital--health-market.html
You may also be interested in the following titles:
Blockchain Technology in Healthcare Market
Autoinjectors
You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The new market report titled “Opportunities in the RNA Therapeutics Market”, published by Roots Analysis is one of the most sought-after solutions for investors operating in the RNA therapeutics market.
The report will help investors stay updated with the latest market trends and opportunities associated with the RNA therapeutics market. The report comes with a concise summary of the details regarding the historical market data, current market trends, future growth prospects, innovator and product landscape, company health indexing, value proposition analysis, company competitiveness, funding and investment, financial analysis of public ventures, business risk analysis, returns on investment and key acquisition targets, as well as the emerging market trends and opportunities in RNA therapeutics market. The opportunities in the RNA therapeutics market are anticipated to expand significantly.
However, the latest report is mainly intended for business leaders, experts, thought leaders, investors, start-ups and growth stage firms interested in RNA Therapeutics business space and is available in the form of PDF and spreadsheet.
Investor Series: Opportunities in the RNA Therapeutics Market:
Investor Series Scope and Market Size:
The report provides detailed information on the RNA therapeutics market, covering the core and peripheral RNA therapeutics solutions. It offers a technical and financial perspective on how the RNA therapeutics market opportunities is likely to evolve, in terms of future business success, over the coming decade. The RNA therapeutics market is broadly segmented on the basis of type of solution, type of therapy, therapeutic area and geographical regions. The segmental growth helps the investors, firms, business leaders to get a lucid picture of the niche pockets of growth, as well as the strategies deployed by the market players to drive the growth of these segments. This section of the report helps them understand and determine the core application areas and the differences between the target markets. The report scrutinizes the RNA therapeutics market in terms of market size & volume and significant information pertaining to product bifurcation and RNA therapeutics solutions overview.
Key Market Contenders:
This particular section of the RNA therapeutics market report covers all the necessary details of the RNA therapeutics’ solutions developed by players operating in the RNA therapeutics market. The report goes on to elucidate a quantitative perspective on the relative health of the different innovator companies and an assessment of the various solutions, offered by the companies developing DTx solutions, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects.
Information on the funding and investment activity that has taken place in this domain since 2011 has also been included in this report. Moreover, the exhaustive report presents financing category-wise trends, describing the relative maturity of the innovator companies. Further, RNA therapeutics market features a list of the leading RNA therapeutics investors , based on their participation in financing activity in this industry segment. It also covers an elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies.
This section of RNA therapeutics market report focusing on the competitive terrain of the RNA therapeutics market endows the reader with every significant detail and information about the leading competitors on the market. The report provides a key acquisition targets analysis, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers and also includes the case study of instances where investors have exited various RNA therapeutics related ventures, offering insights on return on investments made. Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.
Section covered in RNA therapeutics market report:
Section 01: Need for RNA Therapeutics and Innovators Landscape
Section 02: Analysis of Investments
Section 03: Financial Analysis and Assessment of Business Risks
Section 04: Market Forecast and Opportunity Analysis
Section 05: Analysis of Returns on Investment and Key Acquisition Targets
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/opportunities-in-RNA-therapeutics-market.html
You may also be interested in the following titles:
Oral Solid Dosage Manufacturing Market
Lipid Nanoparticles in Drug Delivery
You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The new market report titled ‘CRISPR Technologies: Intellectual Property Landscape,’ published by Roots Analysis features an extensive study of some of the key historical and contemporary intellectual property (IP) documents (featuring granted patents, patent applications and other documents), describing the various types of CRISPR Technologies.
The insights generated in this report have been presented across two deliverables, namely a MS Excel workbook and a MS PowerPoint deck, summarizing the ongoing trend in this domain.
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/crispr-technologies-ip-landscape.html
Main Chapters in the CRISPR Technologies Intellectual Property Landscape Report
Overall Intellectual Property Landscape
An analytical perspective of the various patents and affiliated IP documents that have been published related to CRISPR Technologies, since 2000. An in-depth analysis of published IP documents, representing unique patent families across various global jurisdictions, featuring insightful inferences related to both historical and recent R&D trends within this domain.
Popular / Relevant Prior Art Search Expressions
An examination of IP literature, shortlisting key words and phrases used to describe CRISPR Technologies. The analysis also includes details on the historical use of the aforementioned terms across different IP filings, key affiliated terms and other related trends.
Patent Valuation Analysis
Competitive benchmarking and valuation analysis of the key members of unique patent families captured in the report, taking into consideration important parameters of the patent application.
Patentability and Freedom to Operate
A systematic and Roots Proprietary approach to identify relevant areas of innovation by analyzing published IP documents, by defining the uniqueness of patented / patent pending innovations, in order to assess the scope of patentability in this domain, and pinpoint jurisdictions wherein new and / or modified claims may be filed without infringing on existing IP.
Analysis of Patent Applications and Granted CRISPR Technologies Patents
A detailed summary of the various patent applications and granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis classified the intellectual capital in terms of type of innovation and the innovation related to CRISPR Technologies, thereby offering the means to identify active arenas of research and assess innovation-specific IP filing trends.
Pockets of Innovation and White Spaces
An insightful analysis of the various CPC codes used in published IP literature and their affiliated families, offering the means to identify historical and existing pockets of innovation, the analysis also features a discussion on prevalent white spaces.
Claim Analysis
One of the objectives of the report was to analyze and summarize key inferences from the independent claims mentioned in granted, active patents in the dataset. Using a systematic segregation approach, we have analyzed trends associated with the preamble, type of patent, type of claim and other key elements of a claim.
Key Companies Profiled
10x Genomics
22nd Century Group
64x Bio
Aadigen
Aarhus University
You may also be interested in the following titles:
Quantum Computing in Drug Discovery Services Market
Viral Clearance and Viral Testing Services Market
You may also like to learn what our experts are sharing in Roots educational series:
Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market?
Medical Device Coatings and Modification Technologies
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Roots Analysis has announced the addition of “Modular Facilities in Pharmaceutical and Biotechnology Market (3rd Edition), 2023-2035” report to its list of offerings.
Key Market Insights
Presently, over 50 modular facility providers are engaged in the healthcare market, located across the globe
Currently, more than 250 modular cleanroom providers are offering controlled environments along with accessories in the healthcare domain
The partnership activity for modular facilities in healthcare domain has grown at a CAGR of over 30%, in the past three years, 2018-2021
The projected future opportunity for companies engaged in this field is expected to be well distributed across size of facility, type of industry served, type of modular construct, type of construction component, purpose of facility, scale of operation, type of product, type of expansion, type of modular construction, type of material used and key geographical regions.
An insightful competitiveness analysis of players involved in the modular facilities manufacturing in the healthcare domain
Table of Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Background
3.3. The Concept of Modular Facilities
3.3.1. Types of Modular Constructs
3.3.2. Modular Construction Process
3.4. Modular Construction in the Pharmaceutical Industry
3.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
3.4.2. Modular Pharmaceutical Cleanrooms
3.4.2.1. Cleanroom Classifications and Current Standards
3.4.2.2. Regulations and Standards Concerning Modular Cleanroom Construction
3.5. Advantages of Modular Cleanrooms
3.6. Challenges and Future Prospects
4. MARKET LANDSCAPE: MODULAR FACILITY MANUFACTURERS
4.1. Chapter Overview
4.2. Modular Facility Manufacturers: Overall Market Landscape
4.2.1 Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Year of Establishment and Location of Headquarters
4.2.5. Analysis by Company Size and Location of Headquarters
4.2.6. Analysis by Type of Industry Served
4.2.7. Analysis by Geographical Coverage
4.2.8. Analysis by Type of Industry Served and Geographical Coverage
4.2.9. Analysis by GMP Compliance
4.2.10. Analysis by Geographical Coverage and GMP Compliance
4.2.11. Analysis by Type of Modular Construction
4.2.12. Analysis by Type of Industry Served and Type of Modular Construction
4.2.13. Analysis by Type of Material Used
4.2.14. Analysis by Type of Modular Construction and Type of Material Used
4.2.15. Analysis of Historical and Current Market Landscape Trends
4.2.15.1 Analysis by Company Size, Geographical Coverage and Type of Industry Served
5. MARKET LANDSCAPE: MODULAR CLEANROOM PROVIDERS
5.1. Chapter Overview
5.2. Modular Cleanroom Providers: Overall Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Year of Establishment and Location of Headquarters
5.2.5. Analysis by Company Size and Location of Headquarters
5.2.6. Analysis by Type of Industry Served
5.2.7. Analysis by Location of Headquarters and Type of Industry Served
5.2.8. Analysis by Type of Modular Cleanroom Offered
5.2.9. Analysis by Type of Industry Served and Type of Modular Cleanroom Offered
5.2.10. Analysis by Type of Cleanroom Component Offered
5.2.11. Analysis by Type of Industry Served and Cleanroom Component Offered
5.2.12. Analysis by Type of Modular Cleanroom and Cleanroom Component Offered
5.2.13. Analysis by Location of Headquarters, Type of Industry Served and Type of Modular Cleanroom Offered
5.2.14. Analysis by Quality Certifications Obtained
6. MODULAR FACILITY MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS
6.1 Chapter Overview
6.2 Assumptions / Key Parameters
6.3 Methodology
6.4 Company Competitiveness Analysis: Modular Facility Manufacturers
6.4.1. Company Competitiveness Analysis: Benchmarking of Service Strength
6.4.2. Company Competitiveness Analysis: Benchmarking of Partnership activity
6.4.3. Company Competitiveness Analysis: Small Companies
6.4.4. Company Competitiveness Analysis: Mid-Sized Companies
6.4.5. Company Competitiveness Analysis: Large Companies
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Cytiva
7.2.1. Company Overview
7.2.2. Modular Facility-related Services
7.2.3. Modular Projects
7.2.4. Recent Developments and Future Outlook
7.3. G-Con Manufacturing
7.4. Germfree
7.5. IPM Technologies
7.6. KeyPlants
7.7. ModuleCo Pharma
7.8. NNE
7.9. Pharmadule
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Modular Facility Manufacturers: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Product
8.3.5. Analysis by Type of Partnership and Type of Product
8.3.6. Analysis by Type of Modular Facility
8.3.7. Analysis by Type of Product and Type of Modular Facility
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Location of Partner’s Headquarters
8.3.10. Analysis by Location of Modular Facility
8.3.11. Analysis by Type of Partnership and Location of Modular Facility
8.3.12. Analysis by Type of Product and Location of Modular Facility
8.3.13. Intercontinental and Intracontinental Partnerships
8.3.14. Analysis by Country
9. CASE STUDY ON MODULAR PROJECTS IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY
9.1. Chapter Overview
9.2. Modular Facility Projects Undertaken in the Pharmaceutical and Biotechnology Industry
9.3.1. Analysis by Type of Modular Facility
9.3.2. Analysis by Size of Modular Facility
9.3.3. Most Active Manufacturers: Analysis by Number of Projects Delivered
9.3.4. Most Active Clients: Analysis by Number of Projects Received
9.3.5. Analysis by Location of Modular Facility
9.3.6. Analysis by Type of Facility and Size of Modular Facility
9.3.7. Analysis by Client and Location of Facility
10. FACILITY CONSTRUCTION TRENDS IN THE PHARMACEUTICAL INDUSTRY
10.1. Chapter Overview
10.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry: Historical Data for Top 20 Players
10.2.1. Analysis by Number of Facilities Delivered
10.2.2. Analysis by Type of Facility
10.2.3. Analysis by Purpose of Facility
10.2.4. Analysis by Type of Facility and Purpose of Facility
10.2.5. Analysis by Type of Investment
10.2.6. Analysis by Purpose of Facility and Type of Investment
10.2.7. Analysis by Size of Facility
10.2.8. Analysis by Type of Facility and Size of Facility
10.2.9. Analysis by Purpose of Facility and Size of Facility
10.2.10. Analysis by Location of Headquarters
10.2.11. Analysis by Location of Facility
10.2.12. Analysis by Type of Facility and Location of Facility
11. COST-TIME OPTIMIZATION FRAMEWORK
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Factors Influencing Modular Construction
11.3.1. Intrinsic Factors
11.3.2. Extrinsic Factors
11.4. Cost Efficiency Analysis
11.5. Time-Benefit Analysis
11.6. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Modular Facilities Market in the Pharmaceutical / Biotechnology Sector,
2023-2035
12.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Size of Facility, 2023 and 2035
12.4.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Small Facilities, 2023-203
12.4.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Mid-sized Facilities, 2023-2035
12.4.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Large Facilities, 2023-2035
12.4.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Very Large Facilities, 2023-2035
12.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Industry Served, 2023 and 2035
12.5.1. Modular Facilities Market in the Pharmaceutical Industry, 2023-2035
12.5.2. Modular Facilities Market in the Biotechnology Industry, 2023-2035
12.6. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Modular Construct, 2023 and 2035
12.6.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Hybrid Skid Modular Constructs, 2023-2035
12.6.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Skid-Mounted Modular Constructs, 2023-2035
12.6.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Plug-and-Play Modular Constructs, 2023-2035
12.6.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Truckable Modular Constructs, 2023-2035
12.6.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Modular Constructs, 2023-2035
12.7. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Construction Component, 2023 and 2035
12.7.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Process Equipment, 2023-2035
12.7.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Base Buildings, 2023-2035
12.7.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Mechanical, Electrical and Plumbing Systems, 2023-2035
12.7.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Process Commodities, 2023-2035
12.7.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Construction Components, 2023-2035
12.8 Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Purpose of Facility, 2023 and 2035
12.8.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Manufacturing, 2023-2035
12.8.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Aseptic Filling, 2023-2035
12.8.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Research and Development, 2023-2035
12.8.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Purposes, 2023-2035
12.9. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Scale of Operation, 2023 and 2035
12.9.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Clinical Scale, 2023-2035
12.9.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Commercial Scale, 2023-2035
12.10. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Product, 2023 and 2035
12.10.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Cell and Gene Therapies, 2023-2035
12.10.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Vaccines, 2023-2035
12.10.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Biosimilars, 2023-2035
12.10.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Monoclonal Antibodies, 2023-2035
12.10.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Advanced Pharmaceuticals, 2023-2035
12.10.6. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Sterile Products, 2023-2035
12.10.7. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Viral Vectors, 2023-2035
12.10.8. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Products, 2023-2035
12.11. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Facility, 2023 and 2035
12.11.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for New Facilities, 2023-2035
12.11.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Facility Expansions, 2023-2035
12.11.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Planned Expansions, 2023-2035
12.12. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Modular Construction, 2023 and 2035
12.12.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Relocatable Modular Construction, 2023-2035
12.12.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Permanent Modular Construction, 2023-2035
12.13. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Material Used, 2023 and 2035
12.13.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Steel, 2023-2035
12.13.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Wood, 2023-2035
12.13.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Concrete, 2023-2035
12.14. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Geography, 2023 and 2035
12.14.1. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in North America, 2023-2035
12.14.2. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Europe, 2023-2035
12.14.3. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Asia, 2023-2035
12.14.4. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Middle East and North Africa, 2023-2035
12.14.5. Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Rest of the World,
2023-2035
12.15. Concluding Remaks
13. PREVALENT AND EMERGING INDUSTRY TRENDS
13.1. Chapter Overview
13.2. Adoption of Modular Facilities
13.3. Expansion of Existing Service Portfolio
13.4. Integration of Advanced Technologies
13.4.1. Single-use Technologies
13.4.2. Continuous Processing Technologies
13.4.3. Other Advanced Technologies
14. FUTURE GROWTH OPPORTUNITIES
14.1. Chapter Overview
14.2. Visibility Amongst Start-Ups
14.3. Popularity Amongst Contract Manufacturing Organizations
14.4. Expansion of Existing Facilities
14.5. Adoption for Production of Biosimilars
14.6. Additional Opportunities
14.7. Key Growth Drivers for Modular Construction
14.8. Market Attractiveness in Emerging regions
15. CONCLUSION
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Avon Modular
16.2.2. Interview Transcript: Alan de Zayas (Modular Building Manufacturing and Construction Team)
16.3. Environmental Systems Corporation
16.3.2. Interview Transcript: Vernon Solomon (President)
16.4. Exyte
16.4.2. Interview Transcript: François Abiven (Executive Vice President Global Business Unit BLS) and Luca Mussati (Vice President Technology and Innovation)
16.5. G-Con Manufacturing
16.5.2. Interview Transcript: Maik Jornitz (Chief Executive Officer)
16.6. Modular Devices
16.6.2. Interview Transcript: Mark Koers (Executive Vice President, Sales and Marketing)
16.7. ModWave
16.7.2. Interview Transcript: Pär Almhem (President)
16.8. Subzero Engineering
16.8.2. Interview Transcript: Ward Patton (Director of Sales)
16.9. Vernick
16.9.2. Interview Transcript: Wes Temple (Director of Marketing)
16.10. Zeton
16.10.2. Interview Transcript: Sulogna Roy (Ex-Sales Manager)
17. APPENDIX I: TABULATED DATA
18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/modular-manufacturing-market/178.html
You may also be interested in the following titles:
Pharmaceutical Polymers / Medical Polymers Market
Gene Switch Market
You may also like to learn what our experts are sharing in Roots educational series:
Digital Therapies: The “Digital Pills” of current generation
Medical Device Coatings and Modification Technologies
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
The latest research report titled ‘Deep Learning Market in Drug Discovery and Diagnostics Market’, published by Roots Analysis offers a comprehensive study of the Deep Learning Market in Drug Discovery and Diagnostics industry, while estimating the overall market size and the size and share of the key regional segments of the global market over historical period, as well as the projected timeline of 2023-2035.
The Deep Learning Market in Drug Discovery and Diagnostics market is expected to deliver robust growth over the forecast period, registering an impressive CAGR of 20%. The anticipated market growth is accredited to the significant surge in demand across the regional and global markets for the products and services offered by the Deep Learning Market in Drug Discovery and Diagnostics industry. The latest study provides readers with a granular analysis of the major developmental elements of the global market, potential business avenues, and the overall market dynamics. The report has been specially curated to offer a deep understanding of the competitive terrain of the global market, highlighting the leading market rivals, their market positions, product portfolios, gross revenue shares, profit margins, pricing analysis, sales network & distribution channels, and financial standing.
Segmentation by Therapeutic Areas
Oncological Disorders
Oncological Disorders
Neurological Disorders
Neurological Disorders
Endocrine Disorders
Cardiovascular Disorders
Respiratory Disorders
Ophthalmic Disorders
Musculoskeletal Disorders
Inflammatory Disorders
Key Companies Profiled
Aegicare
Aiforia Technologies
Ardigen
Berg
Google
Huawei
Merative
Nference
Nvidia
Owkin
Phenomic AI
Pixel AI
Report also offer Complimentary Excel Data Packs
Market Landscape Analysis (Drug Discovery)
Market Landscape Analysis (Diagnostics)
Clinical Trial Analysis
Funding Analysis
Start-up Health Indexing
Company Valuation Analysis
Market Sizing and Opportunity Analysis (Drug Discovery)
Market Sizing and Opportunity Analysis (Diagnostics)
Report also includes EXPERT INSIGHTS by
Sean Lane, Chief Executive Officer (Olive)
Junaid Kalia, Founder NeuroCare and Adeel Memon, Assistant Professor, Neurology Specialist (West Virginia University Hospitals)
David Reich, President (The Mount Sinai Hospital) and Robbie Freeman, Vice President of Clinical Innovation (The Mount Sinai Hospital)
Elad Benjamin, Vice President, Business Leader Clinical Data Services (Philips) and Jonathan Laserson, Senior Deep Learning Researcher (Apple)
Kevin Lyman, Founder and Chief Science Officer (Enlitic)
The latest research report specializes in the in-depth analysis of the macroeconomic and microeconomic factors affecting the Deep Learning in Drug Discovery and Diagnostics market development. The report also concentrates on the regulatory framework that is shaping the future of the global market. New and existing pricing structures, emerging application areas, and upcoming investment opportunities have also been detailed in the report. The report further studies the projected growth factors that are expected to influence the market dynamics over the forecast timeframe.
The study is inclusive of a comprehensive analysis of the commonly used marketing and promotional strategies adopted by the key market players. Taking into account the existing market development factors, historical events, and recent market trends, the study presents a balanced opinion on the future scenario of the Deep Learning Market in Drug Discovery and Diagnostics market. It thus supports its opinion by discussing the key corporate strategies, such as mergers & acquisitions, takeovers, joint ventures, and strategic alliances, used by the market players to strengthen their global footprint.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Deep Learning Market in Drug Discovery and Diagnostics market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html
You may also be interested in the following titles:
mRNA Synthesis and Manufacturing Services Market
Digital Twins Market
You may also like to learn what our experts are sharing in Roots educational series:
Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market?
At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Recent advancements in multiplexed profiling and tissue imaging methods have enabled the assessment of spatial heterogeneity in intact tissues; as a result, adoption of spatial omics solutions offering benefits over traditional methods, is increasing
Roots Analysis has announced the addition of “Spatial Genomics, Transcriptomics and Proteomics Solutions Market, 2022-2035” report to its list of offerings.
The Spatial Genomics Market report features an extensive study of the current market landscape and the likely future potential; associated with the spatial omics solutions market, over the next decade. The study also includes a detailed analysis of key drivers and trends within this evolving market. Amongst other elements, the report features:
A detailed overview of the overall market landscape of spatial omics solutions based on several relevant parameters.
A detailed overview of the overall market landscape of players engaged in offering spatial proteomics, transcriptomics and genomics solutions, based on year of establishment, company size, location of headquarters and regional landscape.
A detailed competitiveness analysis of products based on parameters, such as supplier power and product specifications.
Elaborate profiles of key players offering spatial omics solutions.
An analysis of the various partnerships related to spatial omics solutions inked by players engaged in this domain.
An in-depth analysis of patents related to spatial omics solutions, filed / granted, since 2003.
A detailed review of around 600 peer-reviewed, scientific articles related to research on spatial omics solutions.
An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug.
A detailed review of the overall landscape of the live cell instruments market, highlighting the contributions of industry players, along with information on their year of establishment, company size, geographical location of headquarters, ownership and instruments specific parameters.
A detailed review of the overall landscape of sequencing technologies market, highlighting the contributions of industry players, along with information on their year of establishment, company size, geographical location of headquarters, ownership and sequencers specific parameters.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Solution
Instruments
Consumables
Services
Sample Type
DNA
RNA
Protein
Research Area
Oncological Disorders
Immunological Disorders
Neurological Diorders
Infectious Diseases
Others
End User
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Key Geographical Regions
North America
Europe
Asia-Pacific and Rest of the World
Key companies covered in the report
10x Genomics
Akoya Biosciences
Bruker
Canopy Biosciences
NanoString Technologies
Vizgen
Lunaphore Technologies
Molecular Machines & Industries (MMI)
Resolve Biosciences
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/spatial-genomics-market.html
You may also be interested in the following titles:
Cannabis Testing Market
Decentralized Clinical Trials / Virtual Clinical Trials Market
You may also like to learn what our experts are sharing in Roots educational series:
At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector
SARM1: A Potential Therapeutic Target For Neurodegenerative Diseases
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Recent Posts
Roots Analysis has done a detailed study on “AI-ba...
The “Global Bioreactors and Fermenters Market, 202...
Roots Analysis has done a detailed study on Gene S...
Roots Analysis has done a detailed study on “Cell ...